

GLAXOSMITHKLINE PLC  
Form 6-K  
February 19, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors and  
Persons Discharging Managerial Responsibility**

**Vesting of awards made under GlaxoSmithKline's share plans in 2006**

This notification, prepared in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), sets out the vesting of share awards made in 2006, under the GlaxoSmithKline Performance Share Plan.

The three-year performance period for the GlaxoSmithKline Performance Share Plan (PSP) awards made in 2006, which commenced on 1 January 2006, came to an end on 31 December 2008.

The Remuneration Committee of the Board of GlaxoSmithKline plc (GSK) considered the performance achieved in respect of the PSP awards and determined that:

- the PSP awards granted in 2006 to Executive Directors and Corporate Executive Team (CET) members, were dependent on Total Shareholder Return (TSR) performance. These awards lapsed in full because the Company's relative Total Shareholder Return (TSR) performance was below the median of the comparator group;
- the PSP awards granted in 2006 to other senior executives, including individuals who have since been appointed an Executive Director or CET member, were dependent in part on TSR performance and in part on EPS performance. Half of these awards lapsed as GSK's TSR performance was below the median of the comparator group and half of these awards vested as GSK's EPS performance exceeded the target level for full vesting.

The following PSP awards, made in 2006, to the then Executive Directors and CET members, who are all persons discharging managerial responsibility (PDMRs), have not vested and have therefore lapsed.

| <b>Awards that have not vested and therefore lapsed</b> | <b>Ordinary Shares</b> | <b>ADSs</b> |
|---|------------------------|-------------|
| Mr A P Witty*   | 77,000                 |             |
| Mr J S Heslop*  | 100,000                |             |
| Mr J M Clarke   | 77,000                 |             |
| Mr M Dunoyer  | 29,000                 |             |
| Mr D J Phelan   |                        | 38,500      |
| Mr D Pulman   |                        | 25,000      |

\* Denotes an Executive Director.

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Half of the PSP awards, made in 2006, to senior executives who have since been appointed Executive Directors or CET members, vested on 18 February 2009 and half of the awards lapsed, as set out in the table below.

|                  | <b>Number<br/>of Ordinary Shares / ADSs<br/>vesting</b> |             |
|------------------|---|-------------|
|                  | <b>Ordinary Shares</b>                                  | <b>ADSs</b> |
| Dr M M Slaoui*   | 15,049  |             |
| Mr S M Bicknell  | 3,152   |             |
| Mr E J Gray      | 6,676   |             |
| Mr D Learmouth   | 3,152   |             |
| Mr W C Louv      |   | 2,955       |
| Mr D S Redfern   | 6,676   |             |
| Mr J R Stéphenne | 15,049  |             |
| Ms C Thomas      | 5,024   |             |

\* denotes an Executive Director

The Company, Directors, and PDMRs were advised of these transactions on 19 February 2009.

V A Whyte  
Deputy Company Secretary

19 February 2009

### **Enquiries:**

|                                      |                 |                 |
|--------------------------------------|-----------------|-----------------|
| UK Media enquiries:                  | Philip Thomson  | (020) 8047 5502 |
|                                      | David Outhwaite | (020) 8047 5502 |
|                                      | Stephen Rea     | (020) 8047 5502 |
| US Media enquiries:                  | Nancy Pekarek   | (919) 483 2839  |
|                                      | Mary Anne Rhyne | (919) 483 2839  |
|                                      | Kevin Colgan    | (919) 483 2839  |
|                                      | Sarah Alspach   | (215) 751 7709  |
| European Analyst/Investor enquiries: | David Mawdsley  | (020) 8047 5564 |
|                                      | Sally Ferguson  | (020) 8047 5543 |
|                                      | Gary Davies     | (020) 8047 5503 |

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419  
Jen Hill (215) 751 7002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 19 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc